🔍 Description:

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), used primarily to reduce visceral fat in HIV patients with lipodystrophy. Beyond its primary application, Tesamorelin has garnered interest in the fields of anti-aging and metabolic health due to its ability to stimulate the natural production of growth hormone (GH), which can lead to improved body composition, enhanced cognitive function, and overall vitality.

💪 Health Benefits:

– Visceral Fat Reduction: Tesamorelin is particularly effective at reducing visceral fat, especially in individuals with HIV-associated lipodystrophy. This fat reduction not only improves physical appearance but also lowers the risk of cardiovascular diseases associated with excess abdominal fat.

– Growth Hormone Stimulation: By increasing endogenous growth hormone levels, Tesamorelin helps to improve muscle mass, reduce fat, and enhance physical performance. It also plays a role in tissue repair and overall metabolic health.

– Cognitive Function: Emerging research suggests that Tesamorelin may have neuroprotective effects, potentially improving cognitive function in individuals with mild cognitive impairment. This is likely due to its influence on neurotransmitter levels in the brain.

– Nerve Regeneration: Preliminary studies indicate that Tesamorelin may aid in the recovery from peripheral nerve damage, making it a potential therapeutic option for enhancing nerve regeneration following injury or surgery.

💉 Dosing/Administration:

– Typical Dosage: The standard dosage for Tesamorelin is 1-2 mg daily, administered subcutaneously, usually before bedtime to align with the body’s natural growth hormone release cycle.

– Administration Method: Subcutaneous injection, typically in the abdominal area, is the most common method of administration. It is recommended to administer the injection at least 90 minutes after eating to maximize effectiveness.

– Cycling: Tesamorelin is often used in cycles, especially when targeting specific health goals such as fat reduction or cognitive improvement. Cycles can vary in length, but regular breaks are advised to prevent potential desensitization and manage side effects.

⚠️ Side Effects and Safety:

– Common Side Effects: Users may experience mild side effects, such as injection site reactions (e.g., redness, swelling, discomfort), nausea, muscle pain, and mild increases in blood sugar levels.

– Serious Side Effects: In rare cases, Tesamorelin may cause more severe reactions, such as shortness of breath, systemic allergic responses, or significant increases in blood sugar levels, leading to glucose intolerance.

– Safety Profile: Tesamorelin is generally considered safe when used under medical supervision, particularly in the treatment of HIV-associated lipodystrophy. However, for off-label uses, such as anti-aging or neuroprotective purposes, careful monitoring by a healthcare provider is essential to ensure safety and efficacy.

🔬 Research Insights:

– Fat Reduction Efficacy: Studies consistently demonstrate that Tesamorelin effectively reduces visceral fat in HIV-infected individuals with lipodystrophy. In clinical trials, patients treated with Tesamorelin showed significant reductions in abdominal fat and improved insulin sensitivity, with associated enhancements in body image and metabolic health.

– Cognitive Function Enhancement: Preliminary studies suggest that Tesamorelin may positively affect neurotransmitter levels in the brain, potentially delaying or mitigating cognitive decline in aging individuals. This makes it a promising candidate for further research in the field of neurodegenerative diseases.

– Peripheral Nerve Health: Tesamorelin has shown potential in promoting peripheral nerve regeneration following injury. This makes it a subject of interest in regenerative medicine, particularly for conditions that involve nerve damage.

References:

1. Dhillon S. “Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.” *Drugs*. 2011 May 28;71(8):1071-91. doi: 10.2165/11202240-000000000-00000. PMID: 21668043.

2. Egrifta FDA Approval History – Drugs.com. (2022). Retrieved from [Drugs.com](https://www.drugs.com/history/egrifta.html).

3. Macintyre JG. “Growth hormone and athletes.” *Sports Med.* 1987 Mar-Apr;4(2):129-42. doi: 10.2165/00007256-198704020-00004. PMID: 3299611.

4. Patel, A., et al. “Tesamorelin: A hope for ART-induced lipodystrophy.” *Journal of Pharmacy & Bioallied Sciences*. 2011;3(2):319-320. doi:10.4103/0975-7406.80763.

5. Falutz J, et al. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” *N Engl J Med*. 2007;357(23):2359-70. doi: 10.1056/NEJMoa072375.

6. Canadian Agency for Drugs and Technologies in Health (2016). “Clinical review report: Tesamorelin (Egrifta).” Retrieved from [NCBI](https://www.ncbi.nlm.nih.gov/books/NBK539124/).

7. Mangili, A., et al. “Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat.” *PloS one*. 2015;10(10).

8. Tuaha, S. H., et al. “Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury.” *Expert Opinion on Therapeutic Targets*. 2016;20(10):1259-1265.

9. Friedman SD, Baker LD, Borson S, et al. “Growth Hormone–Releasing Hormone Effects on Brain γ-Aminobutyric Acid Levels in Mild Cognitive Impairment and Healthy Aging.” *JAMA Neurol*. 2013;70(7):883–890. doi:10.1001/jamaneurol.2013.1425.

10. Adrian, S., et al. “The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.” *J Frailty Aging*. 2019;8(3):154–159. doi:10.14283/jfa.2018.45.

Introduction to Tesamorelin  

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that has been studied for its potential in addressing excess abdominal fat, muscle fat, and muscle area in individuals with HIV. It has also been explored for its effects on non-alcoholic fatty liver disease (NAFLD) and fat quality independent of changes in fat quantity. Tesamorelin has shown promise in improving body composition and addressing specific symptoms related to growth hormone deficiency in various clinical studies  

How Tesamorelin Works  

Tesamorelin functions as a growth hormone-releasing hormone (GHRH) analog, stimulating the release of growth hormone. It has been studied for its effects on reducing visceral adipose tissue (VAT), increasing muscle area, and improving fat quality. Tesamorelin’s mechanism of action involves targeting the growth hormone axis to address specific metabolic and body composition concerns  

Benefits of Tesamorelin  

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog with various uses and benefits. Unlike some other growth hormone-releasing peptides, Tesamorelin has not been linked to significant effects on other pituitary hormones and respective mechanisms of the body.  

– Reduced visceral fat: Tesamorelin has been shown to decrease visceral adipose tissue (VAT) in both men and women. This makes it a potential treatment for individuals with excess abdominal fat, such as those with HIV-associated lipodystrophy.  

– Increased muscle mass: Tesamorelin has been associated with increased muscle mass, which can be beneficial for individuals looking to improve their body composition and overall strength.  

– Improved cardiovascular health: Tesamorelin has shown to decrease carotid intima-media thickness (cIMT) and c-reactive protein (CRP), indicating potential benefits for cardiovascular health.  

– Reduced liver fat: In the treatment of HIV-associated lipodystrophy, Tesamorelin has been shown to reduce liver fat. This can be beneficial for individuals with liver-related issues.  

– Improved cognitive function: Tesamorelin has been reported to improve cognitive function in older individuals and patients at increased risk of Alzheimer’s disease due to mild cognitive impairment.  

Dosing Protocols  

The suggested initial dose of Tesamorelin is 1mg daily to assess tolerance, then increase to up to 2mg daily. It is administered as a subcutaneous injection.  

Side Effects  

The potential side effects of taking Tesamorelin, as reported by various sources, include bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, rash, swelling of the face or throat, depressed mood, insomnia, night sweats, muscle spasm, nausea, vomiting, upset stomach, pain, redness, itching, swelling, bruising, bleeding, or other irritation at the injection site, muscle aches, pain or stiffness in the muscles or joints, wrist pain or numbness, numbness or tingling in the hands or fingers, pounding heartbeats or fluttering in the chest, high blood sugar, sleep problems, and mild rash or itching. It is important to consult with a healthcare professional for personalized advice and to monitor for any potential adverse effects when considering the use of Tesamorelin.

Disclaimer  

The information provided here is based on scientific research and should not replace professional medical advice. Individuals considering the use of Tesamorelin for therapeutic purposes should consult with a qualified healthcare provider to discuss its potential benefits and risks, as well as to receive personalized dosing recommendations based on their specific health needs and medical history.

Super short cliff notes..

– extreme excess of GH and IGF are associated with cancer as seen in people with true acromegaly 

– unclear at what GH/IGF level and what exposure time is needed to increase the risk of cancer

– cancer cells usually arise from genetic mutation from error of DNA copying during cellular proliferation, so statistically speaking, more cellular division = more chance of DNA replication error, it’s like, the more your drive on the road, the higher your likelihood of car accident. Of course it’s not the only factor, there are MANY other factors affecting this, example:

Person A is a good driver and only drives 1,000 miles per year

Person B is also a good driver but drives 100,000 miles per year

Person C is a bad driver AND drives 100,000 miles per year

Person D is bad driver, drives 100,000 miles, and driving in a place with terrible & small roads.

So the person A has lower risk of accident than B, because even though they’re equally good drivers, person B spend a lot more time on the road so more chances to have accident, simple statistics.

Person B & C drive same amount but C has more risk factors (bad driving) so person B has lower risk of accident than person C.

And person D, obviously has the highest risk of all 

So think of cellular proliferation as “amount of miles per year”. It’s a factor but it’s far from being the only factor (it’s not even close to being the most important factor, but still a factor).

So GH secretagogues, theoretically may increase the risk but it’s never been conclusively proven yet. Because probably such a study, to be valid, needs at least 2 things:

1. A long study time, we’re talking at least 20-30 years of study and using GH secretagogues (not sure who will fund it)

2. Needs to drive up the GH or IGF level to really supratherapeutic range INTENTIONALLY, that kind of study is probably medically unethical and will run into trouble with Institutional Review Board (IRB) prior to even starting such study

So no, we don’t know if prolonged use of GH secretagogues can “cause” cancer and at what level. What we should probably be more concerned though is that if you ALREADY have a tumor/cancer, it may make it grow larger much faster. Again, I’m not sure there’s definitive evidence because who in their right mind will use GH secretagogues knowing they have a growing cancer? 

And no scientist will conduct such a study in humans, rightfully so.

But it’s a very very plausible concern.

I’ll try a brief breakdown So physiologically it goes like this:

– GHRH secretion by hypothalamus 

  ⬇️ stimulates

– GH secretion by pituitary

⬇️ GH to liver to induce

– IGF-1 synthesis by liver

⬇️

– IGF and GH together bring about the end-organ effects

So, while it is TRUE and well documented that GH production goes lower as we get old, the question is why… Where is the weak link in that process above?

Possibilities:

1. Hypothalamus produces less GHRH

2. Pituitary becomes less responsive to GHRH, this producing less GH despite the same amount of GHRH

The answer is #1. See some of the studies from past:

https://academic.oup.com/jcem/article-abstract/84/10/3490/2660505?redirectedFrom=fulltext

https://academic.oup.com/jcem/article-abstract/62/3/595/2674769?redirectedFrom=fulltext&login=true

I think we have to be precise and differentiate between “half life” vs how long it “stays elevated or back to baseline”. Those are 2 different concepts.

Half life works like this: its the time it takes for IGF to go down to half its original amount/concentration, but this applies only if NO NEW IGF is given/produced. In this concept, the half life of IGF in healthy ADULT is actually only around… Maybe 12-17 hours depending on which study data you use.

So then why does it take 2-3 weeks for your IGF level to go back to baseline even after you stop using tesa? Because your body doesn’t stop producing IGF. Even if you stop tesa, your body still produces GH and IGF at a progressively lower amount when you stop tesa. So while your serum IGF is being eliminated, there’s “fresh IGF” joining the fray, so it takes much longer for your IGF level to finally be back at baseline.

So TLDR:

1. Half life of IGF = 12-17 hours average

2. Time it takes for your serum IGF level to go back to baseline: 2-3 weeks average